Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00920959 · ClinicalTrials.gov registry record · Phase 3
Advair Pediatric Once-Daily
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 908
- Enrollment target
NCT00920959 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 908 participants.
The verdict
NCT00920959, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 908 participants
- Enrollment target
Study Summary
To demonstrate if once-daily dosing of ADVAIR 100/50 once-daily has superior efficacy and comparable safety compared with FP 100mcg once-daily in pediatric subjects 4 to 11 years of age with asthma.
Interventions
- DRUG Placebo
- DRUG FP 100mcg
- DRUG FSC 100/50mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 908 participants |
| Start Date | 2001-11 |
| Est. Completion | 2004-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00920959
The ClinicalTrials.gov registry entry for NCT00920959 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 908 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00920959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00920959 about?
NCT00920959 is a clinical study titled "Advair Pediatric Once-Daily". To demonstrate if once-daily dosing of ADVAIR 100/50 once-daily has superior efficacy and comparable safety compared with FP 100mcg once-daily in pediatric subjects 4 to 11 years of age with asthma.
What is the current status of trial NCT00920959?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 908 participants. The study started on 2001-11. Estimated completion is 2004-01.
What interventions are being tested in trial NCT00920959?
The interventions under investigation include: Placebo (DRUG), FP 100mcg (DRUG), FSC 100/50mcg (DRUG).
Who is sponsoring clinical trial NCT00920959?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.